Emma Andrus, Associate Editor

The botanical blend also demonstrated potential to protect the skin from free radical damage on a cellular level, the study found.

The study will evaluate rezpegaldesleukin and its effect on Severity of Alopecia Tool scoring by the conclusion of a 36-week period.

The approval also marks the first and only approved HA dermal filler approved in the US for use in the upper face.

We want to know: Will you be attending the conference in San Diego later this week?

Keep up with the latest headlines in dermatology from the past week, including a physician working to address the overlooked issue of skin diseases in Black patients, the initiation of a Good Laboratory Practice toxicology study for topical treatment DB-007-4, and more.

The EACH one TEACH one program aims to enhance access to dermatologic care for residents of southeast Washington, DC, Wards 7 and 8.

Dermatology Times asked our readers to share what conferences they are looking forward to in the first quarter of 2024.

Dermatology Times is looking back on the top stories in dermatology from the month of February.

Today is Rare Disease Day. Here's a look back at news related to rare skin conditions over the past year.

The collaboration with Sato marks a continued effort of Arcutis to collaborate with pharmaceutical companies and license topical roflumilast in Asia.

Dermatology Times is recapping our top expert interviews from the month of February.

Adamson recently shared with Dermatology Times about the significance of Vaseline's Mended Murals initiative and the role of dermatologists in improving patient access.

We want to hear from you. Please take the time to respond to our survey.

Findings regarding an association between HS severity and dietary elements such as vitamin D, B12 supplementation, and more, are inconclusive.

Long-term treatment showed increased efficacy in patients who responded partially in week 52, indicating the importance of extended therapy for maximizing benefits in certain individuals.

Researchers involved in the review said this increase may help lead to more patient education and more tailored products for patients from this region.

Maternal mental health conditions are associated with the majority of atopic diseases, according to a study.

Keep up with the latest headlines in dermatology from the past week, including the rise of dermatologists offering skin health services for people of color, isotretinoin and its ocular impact, and more.

Researchers compared the potent depigmenting agent with modified Kligman's formula, considered the gold standard therapy for melasma.

Learn more about dupilumab-induced conjunctivitis rates and misconceptions, the thriving long-term efficacy of dupilumab over 3 years, and unraveling the itch-flare dynamic in abrocitinib treatment.

In a recent study, topical ruxolitinib improved clinical outcomes, itch, and patient quality of life.

The initiative brings awareness and action for people of color to the forefront of the conversation.

The data was recently published in the Journal of the American Academy of Dermatology International.

Researchers utilized studies and papers from the review to define and understand best practices and methods for improving adherence.

Officials recently reported the first known fatality from the virus. Here's what health professionals say to watch for.

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.

Almirall now possesses the rights to develop and commercialize NN-8828, particularly in immune inflammatory dermatological diseases.

Keep up with the latest headlines in dermatology from the past week, including the commercialization of a skin cancer diagnostic AI in South Korea, cannabis extract's potential in combatting melanoma cells, and more.

The combination therapy did not yield any effect in patients with non-segmental vitiligo and prompts additional large studies prior to conclusive efficacy.

The IFPA Forum Roadmap for Asia outlines key advocacy demands and practical strategies to improve psoriatic care throughout the continent.